Obesity

Setting the Stage for Obesity Care

Obesity is a complex, chronic disease characterized by excessive adiposity that negatively impacts health. It is a major risk factor for numerous comorbid conditions including type 2 diabetes, cardiovascular disease, hypertension, dyslipidemia, obstructive sleep apnea, and certain cancers.^[1] On the Family Nurse Practitioner (FNP) board exam, obesity is a high-yield topic covering pathophysiology, assessment using body mass index (BMI) and waist circumference, evidence-based treatment algorithms, and chronic management strategies. Mastery of this topic is essential for primary care practice, where FNPs increasingly lead weight management interventions.^[2]

Structural Parameters of Obesity Assessment

• Body Mass Index (BMI): Weight in kilograms divided by height in meters squared (kg/m²). Classification per CDC/WHO:
  • Normal: 18.5–24.9
  • Overweight: 25.0–29.9
  • Class I Obesity: 30.0–34.9
  • Class II Obesity: 35.0–39.9
  • Class III Obesity (Severe): ≥40.0
• Waist Circumference: Independent marker of central adiposity and cardiometabolic risk. Elevated if ≥102 cm (40 in) in men or ≥88 cm (35 in) in women (non-pregnant, non-Asian cutoffs). For Asian populations, lower thresholds apply: ≥90 cm men, ≥80 cm women.^[1]
• Adiposopathy: Pathologic dysfunction of adipose tissue leading to inflammation, insulin resistance, and metabolic syndrome.^[3]
• Energy Balance: Chronic positive energy balance (calories in > calories out) results in weight gain; both genetic and environmental factors influence susceptibility.
• Obesity Phenotypes: Metabolic obesity (normal weight but metabolically unhealthy), sarcopenic obesity (low muscle mass with high fat), and healthy obesity (obese but no metabolic abnormalities — still carries long-term risk).

Adipose Pathophysiology and Chronic Disease Framework

Pathophysiology Overview

Obesity involves complex interactions between the hypothalamus, gut hormones (ghrelin, peptide YY, GLP-1), adipokines (leptin, adiponectin), and genetic predisposition. Leptin resistance impairs satiety signaling.^[3] Chronic inflammation from visceral adipose tissue leads to insulin resistance and endothelial dysfunction.

Chronic Disease Management Framework (5A's Model)

1. Ask: Screen all adults for obesity annually using BMI. Use a non-judgmental approach.
2. Assess: Evaluate degree of obesity, comorbid conditions, readiness to change, barriers, and prior weight loss attempts.
3. Advise: Educate on health risks and benefits of modest weight loss (5–10% of baseline body weight yields significant metabolic improvement).
4. Agree: Collaboratively set realistic goals (e.g., 1–2 lb/week loss, dietary changes, physical activity targets).
5. Assist: Provide or refer for intensive lifestyle interventions, pharmacotherapy, or bariatric surgery as indicated.^[4]

Intensive Lifestyle Intervention (ILI)

• Core component: reduced-calorie diet (typically 1200–1500 kcal/day for women, 1500–1800 for men) combined with ≥150 minutes/week of moderate-intensity physical activity.
• Behavioral strategies: self-monitoring, stimulus control, problem-solving, relapse prevention.
• Typically delivered through structured programs (e.g., Diabetes Prevention Program, Look AHEAD).^[2]

Recognizing Obesity's Clinical Manifestations

• Anthropometric: Elevated BMI, increased waist circumference, increased neck circumference (may suggest sleep apnea).
• Metabolic: Acanthosis nigricans (insulin resistance), hirsutism (PCOS), central adiposity with striae (Cushing's syndrome).
• Associated conditions: Fatigue, dyspnea on exertion, joint pain (weight-bearing joints), snoring, daytime somnolence, GERD, urinary incontinence, depression.
• Physical exam findings: Hepatomegaly (NAFLD), ankle edema, elevated blood pressure, elevated heart rate.^[5]

Structured Obesity Diagnosis and Risk Stratification

Screening and Diagnosis

• BMI calculation at every annual visit. Use weight and height measured, not self-reported.
• Waist circumference in patients with BMI 25–35 to further stratify cardiometabolic risk.
• Comorbidity evaluation: Fasting glucose or HbA1c (diabetes), lipid panel, blood pressure, liver enzymes (ALT/AST), TSH (if symptoms of hypothyroidism).^[1]
• Further testing if secondary causes suspected: overnight dexamethasone suppression test (Cushing's), free testosterone (PCOS), genetic testing if early-onset severe obesity.

Staging Obesity

The Edmonton Obesity Staging System (EOSS) uses BMI plus functional and medical severity (stages 0–4). This is exam-relevant: a patient may have Class III obesity but no comorbidities (EOSS 0) vs Class I with severe complications (EOSS 3). Treatment aggressiveness increases with EOSS stage.^[6]

Evidence-Based Obesity Treatment Spectrum

Lifestyle Modification (First-Line)

• Dietary interventions: Hypocaloric diets (e.g., Mediterranean, DASH, low-carb) are all effective when caloric deficit is achieved. Very low-calorie diets (<800 kcal/day) require medical supervision.
• Physical activity: 150–300 min/week of moderate-intensity aerobic activity plus resistance training 2x/week for weight maintenance.
• Behavioral therapy: Cognitive-behavioral therapy, motivational interviewing, group support.^[2]

Pharmacotherapy

Consider for patients with BMI ≥30 or ≥27 with weight-related comorbidity, after lifestyle intervention. Medications approved for chronic weight management (exam-high-yield):

^[7]

Bariatric Surgery

• Indicated: BMI ≥40 or BMI ≥35 with significant obesity-related comorbidities (e.g., T2DM, OSA, NAFLD).
• Most common procedures: Roux-en-Y gastric bypass (RYGB), sleeve gastrectomy, adjustable gastric band (less common).
• Post-op monitoring: lifelong vitamin/mineral supplementation (B12, iron, calcium, vitamin D), surveillance for dumping syndrome, hypoglycemia, and nutritional deficiencies.
• RYGB is also highly effective for diabetes remission.^[8]

Risk Mitigation and Safety Monitoring

• Medication safety: Avoid sympathomimetic agents (phentermine) in patients with uncontrolled hypertension, arrhythmia, or CAD. GLP-1 agonists: do not initiate if personal/family history of medullary thyroid carcinoma or MEN2. Educate patients about nausea and risk of acute pancreatitis.
• Surgical risks: Leak, stricture, bleeding, pulmonary embolism, and micronutrient deficiencies. Long-term risk of alcohol use disorder after RYGB due to altered alcohol metabolism.
• Weight stigma: Use person-first language (e.g., "patient with obesity," not "obese patient"). Avoid blaming. Screen for eating disorders (binge eating disorder is common).^[4]
• Rapid weight loss caution: Risk of cholelithiasis, hair loss, electrolyte imbalances. Monitor closely during very low-calorie diets.

Strategic Exam Preparation for Obesity

• Remember: BMI is a screening tool, not a diagnostic criterion for health. A muscular athlete may have BMI >30 but very low body fat.
• First-line treatment is always lifestyle unless comorbidities dictate otherwise. Pharmacotherapy is adjunctive, not first-line.
• Know the thresholds for surgery: BMI ≥40 or ≥35 with comorbidity – this is heavily tested.
• Drug interactions: Orlistat may reduce absorption of levothyroxine and cyclosporine – separate by at least 3–4 hours.
• Liraglutide vs semaglutide: Both are GLP-1 agonists; semaglutide has greater weight loss efficacy (≈15% vs ≈8% body weight).
• "Red flag" symptoms for bariatric complications: abdominal pain, nausea/vomiting, dysphagia, tachycardia, fever – suspect leak.
• Obesity paradox: In certain chronic diseases (e.g., heart failure, CKD), mild obesity may be associated with better survival – but this does not negate the need for weight management in general population.^[9]
• Memory aid for weight loss drug classes: "Phen & Top" (phentermine/topiramate) – think "stimulant + anticonvulsant"; "Nal & Bup" (naltrexone/bupropion) – think "anti-opioid + antidepressant"; "GLP-1" – think "incretin mimic."

References

1. Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. Circulation. 2014;129(25 Suppl 2):S102-S138. https://doi.org/10.1161/01.cir.0000437739.71477.ee
2. US Preventive Services Task Force. Screening for obesity in adults: recommendation statement. JAMA. 2018;320(11):1163-1171. https://doi.org/10.1001/jama.2018.13022
3. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376(3):254-266. https://doi.org/10.1056/NEJMra1514009
4. Apovian CM, Garvey WT, Ryan DH. Challenging obesity: patient care and management. N Engl J Med. 2016;374(2):161-173. https://doi.org/10.1056/NEJMoa1505633
5. Klein S, Burke LE, Bray GA, et al. Clinical implications of obesity with specific focus on cardiovascular disease: a statement for healthcare professionals from the American Heart Association. Circulation. 2004;110(18):2952-2967. https://doi.org/10.1161/01.CIR.0000145546.97738.1E
6. Sharma AM, Kushner RF. A proposed clinical staging system for obesity. Int J Obes. 2009;33(3):289-295. https://doi.org/10.1038/ijo.2009.2
7. Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. Endocr Pract. 2016;22(Suppl 3):1-203. https://doi.org/10.4158/EP161365.GL
8. Arterburn DE, Telem DA, Kushner RF, Courcoulas AP. Benefits and risks of bariatric surgery in adults: a review. JAMA. 2020;324(9):879-887. https://doi.org/10.1001/jama.2020.12567
9. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53(21):1925-1932. https://doi.org/10.1016/j.jacc.2008.12.068